Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for
the prevention and treatment of venous thromboembolic events, that is, deep vein …

Background Obesity is a global epidemic and bariatric surgery is used with increasing
frequency to treat its complications. The extent to which bariatric surgery alters the efficacy …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

The risk of venous thromboembolism following total joint arthroplasty is significantly greater
than those of other types of elective orthopaedic procedures. This risk is increased in obesity …

abstract The class of new oral anticoagulants (NOACs) has been developed to provide
reliable oral anticoagulation without the need for therapeutic drug monitoring. Based on …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …